Ecdysone receptor-based RheoSwitch Therapeutic System transcription factor complex (RTS)

The Ecdysone receptor-based RheoSwitch Therapeutic System (RTS) transcription factor complex is a synthetic, inducible gene regulation platform used primarily in gene therapy to control the expression of therapeutic proteins (Barrett et al., 2018; PMID: 29755109). It is based on the ecdysone receptor (EcR) from insects, which has no natural endogenous ligand or functional homolog in humans, thereby minimizing off-target effects (NIH, 2018; Snippet 1.3.2). The system typically consists of two chimeric proteins: one containing a DNA-binding domain fused to a modified EcR and another containing a transactivation domain fused to a retinoid X receptor (RXR) (NIH, 2015; Snippet 1.3.2). In the presence of a specific small-molecule activator, such as veledimex (RG-115932), these proteins form a heterodimeric complex that binds to a unique promoter to drive the transcription of a transgene, such as Interleukin-12 (IL-12) (Frontiers in Oncology, 2021; Snippet 1.3.4). This technology allows for precise, dose-dependent, and reversible control of protein production, which is particularly valuable for delivering potent but toxic cytokines directly to tumor sites (NIH, 2018; Snippet 1.3.3). Clinical trials have utilized RTS to treat high-grade gliomas and other cancers, demonstrating its ability to induce localized immune responses while maintaining a manageable safety profile (Barrett et al., 2018; PMID: 29755109).

Other names

RheoSwitch Therapeutic SystemRheoSwitchEcR-based gene switchEcdysone receptor-based gene switchAd-RTS-IL-12 system

The RheoSwitch Therapeutic System (RTS) operates as a ligand-inducible gene switch. It consists of two chimeric transcription factors: a DNA-binding domain (typically Gal4) fused to a modified ecdysone receptor (EcR) ligand-binding domain, and a transcriptional activation domain (typically VP16) fused to a chimeric retinoid X receptor (RXR) (NIH, 2015; Snippet 1.3.2). In the absence of a ligand, these components do not form a functional complex. Upon administration of a small-molecule activator such as veledimex, the ligand binds to the EcR subunit, inducing heterodimerization with the RXR subunit. This active complex then binds to specific response elements in a promoter to drive the expression of a therapeutic transgene, such as Interleukin-12 (IL-12) (Barrett et al., 2018; PMID: 29755109).